Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.71 |
| ▸ | JAK3 | P52333 | 11/20 | 0.71 |
| ▸ | BRD4 | O60885 | 2/20 | 0.62 |
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | MERTK | Q12866 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | STK25 | O00506 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.62 |
| ▸ | CASK | O14936 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.62 |
| ▸ | CHUK | O15111 | 1/20 | 0.62 |
| ▸ | MUSK | O15146 | 1/20 | 0.62 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192919 | 0.93 | JAK2 (0.61) | JAK2PTK2JAK3BRD4AXL | |
| SCHEMBL13072927 | 0.90 | JAK2 (0.84) | JAK2PTK2JAK3 | |
| SCHEMBL531322 | 0.87 | JAK2 (0.69) | JAK2PTK2JAK3BRD4AXL | |
| SCHEMBL3200284 | 0.87 | JAK2 (0.52) | JAK2PTK2JAK3BRD4AXL | |
| SCHEMBL13072954 | 0.85 | JAK2 (0.65) | JAK2PTK2JAK3BRD4AXL | |
| SCHEMBL13073007 | 0.84 | JAK2 (0.75) | JAK2PTK2JAK3BRD4PDGFRB | |
| SCHEMBL13032449 | 0.84 | JAK2 (0.81) | JAK2PTK2JAK3AXLABL1 | |
| SCHEMBL2634391 | 0.83 | JAK2 (1.00) | JAK2PTK2JAK3 | |
| SCHEMBL13032297 | 0.83 | JAK2 (0.80) | JAK2PTK2JAK3AXLYES1 | |
| SCHEMBL13276106 | 0.83 | JAK2 (0.75) | JAK2PTK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885PTK2 312/4885JAK3 3/4885 |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885PTK2 312/4885JAK3 3/4885 |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885PTK2 312/4885JAK3 3/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | JAK2 1/4885PTK2 312/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.